A Phase 2 interventional study of OBE022 and Placebos in Preterm Labor, sponsored by ObsEva SA. Status unknown at 18 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-07.
Sponsored by ObsEva SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Obstetric Labor, Premature with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Obstetric Labor, Premature · Israel.
Among the 13 studies in Obstetric Labor, Premature with a site in Israel, this one is one of 2 that started in 2018, is the only one in phase 2, and was the 11th registered.
243 studies on the registry are indexed under Obstetric Labor, Premature; 36 are open to participants now.
Browse Obstetric Labor, Premature studies →1 of the 13 studies in Obstetric Labor, Premature with a site in Israel is open now. Recruiting first, the newest first:
Rambam Health Care Campus · Sites in Israel
Ages 18–45
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 24 Obstetric Labor, Premature studies recruiting now, 14 (58%) set no upper age limit and 9 (38%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is close to the median of 110 across 149 interventional studies indexed under Obstetric Labor, Premature.
Median enrollment 129 across the 9 interventional studies, 250 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
ObsEva SA is the lead sponsor of 10 studies on the registry; none are open to participants now.
ObsEva SA has 2 studies filed under Obstetric Labor, Premature — fewer than ten, so there is no comparison to draw.
1 of the studies in Obstetric Labor, Premature with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05698966Rambam Health Care CampusLow Dose Antenatal Corticosteroids for Late Preterm Delivery | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Obstetric Labor, Premature with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a proof-of-concept study in 2 parts.
In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks.
Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks.
All patients in part A and part B must receive atosiban infusion for 48 hours as standard of care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.
Key Inclusion Criteria:
Part A
Part B
At least one of the following signs of preterm labour:
Key Exclusion Criteria:
Any for the mother or the fœtus to stop labour or prolong pregnancy or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next 7 days, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OBE022 plus atosiban: OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start. * Loading dose: 1 000 mg on Day 1. * Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2. * Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7) Atosiban will be administered over 48h as per label.
Drug: OBE022 · Drug: Atosiban
OBE022 matching placebo plus atosiban: OBE022 matching placebo administration will follow the same regimen as the active group. Atosiban will be administered over 48h as per label.
Drug: Placebos · Drug: Atosiban
Oral
Oral
I.V.
Incidence of delivery within 2 days (48 h) from start of IMP administration
Time frame: 48 hours
Incidence of delivery within 7 days (168 h) from start of IMP administration
Time frame: 168 hours
Incidence of delivery before 37 weeks of GA
Time frame: Up to 13 weeks from start of IMP administration
Time to delivery measured from start of IMP administration
Time frame: Up to 17 weeks from start of IMP administration
Maternal incidence of AEs from Day 1 until 28 days after birth.
Time frame: 28 days after birth
Maternal incidence of TEAEs from Day 1 until 28 days after birth.
Time frame: 28 days after birth
Maternal incidence of clinically significant changes in laboratory safety tests, from Day 1 until 28 days after birth.
Time frame: 28 days after birth
Maternal incidence of clinically significant changes in vital signs, from Day 1 until 28 days after birth.
Time frame: 28 days after birth
Incidence of AEs indicating fœtal distress such as growth retardation and/or changes in fœtal heart rate monitoring and/or amniotic fluid index (AFI) from Day 1 to Day 7 and Day 14 (or earlier if birth).
Time frame: Up to 14 days after start of IMP administration
In Part A only: Incidence of fœtal adverse events in relation with the cardiovascular function assessed by Doppler ultrasound on Day 1 to 3 and Day 7 from IMP start.
Time frame: Up to 7 days after start of IMP administration
Incidence of infants experiencing adverse events from birth until 28 days after birth.
Time frame: Up to 28 days after birth
Incidence of infants experiencing clinical significant changes in vital signs from birth until 28 days after birth.
Time frame: Up to 28 days after birth
Apgar score.
The score is a rapid method for assessing a neonate immediately after birth. Elements of the Apgar score include color, heart rate, reflexes, muscle tone, and respiration, each weighted evenly and assigned a value of 0, 1, or 2. The components are then added together to give a total score (0 to 10) that is recorded at 1 and 5 minutes after birth.
Time frame: At birth, at 1 minute and 5 minute
Weight.
Time frame: At birth and 28 days after birth.
Head circumference.
Time frame: At birth and 28 days after birth.
Incidence of infants experiencing prematurity-related events
Time frame: At birth.
Incidence of duration of hospitalization and or re-admission to hospital.
Time frame: Up to 28 days after birth.
Incidence of infants with one or more Ages and Stages Questionnaire® domain score(s) below the cut-off score at 6 months, 12 months and 24 months of age, adjusted for gestational age at birth.
The Ages and Stages Questionnaire (ASQ) is a parent-completed questionnaire designed to be used as a general developmental screening tool. The ASQ-3 covers five areas of child development that includes: personal social, gross motor, fine motor, problem solving, and communication. Parents complete the questionnaire independent of professionals, indicating for each item "yes" if child performs the item, "sometimes" indicating an occasional or emerging skill, or "not yet" indicating that the child does not yet perform the behavior
Time frame: Up to 24 months
Plasma concentration of OBE022/OBE002 at Day 1, Day 2, Day 3 and Day 7.
Time frame: Up to 7 days after start of IMP administration
Pharmacokinetic parameters of OBE022/OBE002 at Day 7
Area under the curve (AUC)
Time frame: Day 7
Pharmacokinetic parameters of OBE022/OBE002 at Day 7
Maximal concentration (Cmax)
Time frame: Day 7
Pharmacokinetic parameters of OBE022/OBE002 at Day 7
Half-life.
Time frame: Day 7
Fœtal (cord blood)-maternal OBE002 concentration ratio at the time of delivery for patients who received IMP treatment within the previous 24 h.
Time frame: Day of delivery
Changes in uterine contractions as assessed by electrohysterography, tocodynamometry or abdominal palpation at each hour during the first 6 hours after IMP start.
Time frame: Up to 6 hours after IMP start.
Plan to share: No
Ran from Jan 2018 to primary completion in Jul 2020, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ObsEva SA